Basic treatment considerations using chemotherapy for patients with small cell lung cancer

被引:39
作者
Johnson, BE
Jänne, PA
机构
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
关键词
D O I
10.1016/j.hoc.2003.12.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Small cell lung cancer (SCLC) was initially recognized as an entity distinct from other types of lung cancer by pathologic examination in 1926 by Dr. Barnard [1]. It has been commonly referred to as oat cell carcinoma because of its cytologic resemblance to grains of oats. The World Health Organization International Histological Classification of Tumours has now adopted the designation of small cell carcinoma rather than oat cell carcinoma [2]. SCLC is recognized as a malignant epithelial tumor consisting of small cells with scant cytoplasm, ill-defined borders, finely granular nuclear chrornatin, and absent or inconspicuous nucleoli [2-4]. The cells are round, oval, and spindle-shaped, and nuclear molding is prominent (Fig. 1). The mitotic rate is high. The most effective treatment for most lung cancer is surgical resection. Most patients cured of their localized lung cancer undergo a surgical resection; nearly all have non-SCLC (NSCLC). SCLC represents approximately 15% of the lung cancers presenting in patients in the United States [5]. SCLC rarely is treated successfully with surgery because SCLC is typically disseminated at the time of presentation. The patients who appear to have localized disease and are treated with surgical resection relapse and die of their SCLC most of the time [6,7]. The natural history of SCLC from the time of diagnosis to death is very short. The survival of patients diagnosed with SCLC and followed within the Veterans Administration Medical System was 2 months for patients with extensive-stage SCLC and 3 months for patients with limited-stage SCLC [8]. These fundamental observations on the clinical behavior of SCLC have led to adoptions of combination chemotherapy as the initial effective therapy in most Fig. 1. Photomicrograph of SCLC. The specimen is a diagnostic specimen from a patient with limited-stage SCLC. The small cells are round or oval with scant cytoplasm, ill-defined borders, finely granular nuclear chromatin, and inconspicuous nucleoli with prominent nuclear molding. (Hematoxylin-eosin, original magnification x 100).
引用
收藏
页码:309 / +
页数:16
相关论文
共 69 条
  • [1] PROSPECTIVE-STUDY OF ETOPOSIDE SCHEDULING IN COMBINATION CHEMOTHERAPY FOR LIMITED DISEASE SMALL-CELL LUNG-CARCINOMA
    ABRATT, RP
    WILLCOX, PA
    DEGROOT, M
    GOODMAN, HT
    JANSEN, ER
    SALTON, DGM
    [J]. EUROPEAN JOURNAL OF CANCER, 1991, 27 (01) : 28 - 30
  • [2] Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: A prospective European organization for research and treatment of cancer-lung cancer group phase III trial-08923
    Ardizzoni, A
    Tjan-Heijnen, VCG
    Postmus, PE
    Buchholz, E
    Biesma, B
    Karnicka-Mlodkowska, H
    Dziadziuszko, R
    Burghouts, J
    van Meerbeeck, JP
    Gans, S
    Legrand, C
    Debruyne, C
    Giaccone, G
    Manegold, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) : 3947 - 3955
  • [3] Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
    Ardizzoni, A
    Hansen, H
    Dombernowsky, P
    Gamucci, T
    Kaplan, S
    Postmus, P
    Giaccone, G
    Schaefer, B
    Wanders, J
    Verweij, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 2090 - 2096
  • [4] INITIAL CHEMOTHERAPEUTIC DOSES AND SURVIVAL IN PATIENTS WITH LIMITED SMALL-CELL LUNG-CANCER
    ARRIAGADA, R
    LECHEVALIER, T
    PIGNON, JP
    RIVIERE, A
    MONNET, I
    CHOMY, P
    TUCHAIS, C
    TARAYRE, M
    RUFFIE, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (25) : 1848 - 1852
  • [5] The nature of the "oat-celled sarcoma" of the mediastinum.
    Barnard, WG
    [J]. JOURNAL OF PATHOLOGY AND BACTERIOLOGY, 1926, 29 (03): : 241 - 244
  • [6] Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma
    Bonner, JA
    Sloan, JA
    Shanahan, TG
    Brooks, BJ
    Marks, RS
    Krook, JE
    Gerstner, JB
    Maksymiuk, A
    Levitt, R
    Mailliard, JA
    Tazelaar, HD
    Hillman, S
    Jett, JR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2681 - 2691
  • [7] CHEMOTHERAPY ALONE OR CHEMOTHERAPY WITH CHEST RADIATION-THERAPY IN LIMITED STAGE SMALL-CELL LUNG-CANCER - A PROSPECTIVE, RANDOMIZED TRIAL
    BUNN, PA
    LICHTER, AS
    MAKUCH, RW
    COHEN, MH
    VEACH, SR
    MATTHEWS, MJ
    ANDERSON, AJ
    EDISON, M
    GLATSTEIN, E
    MINNA, JD
    IHDE, DC
    [J]. ANNALS OF INTERNAL MEDICINE, 1987, 106 (05) : 655 - 662
  • [8] CAVALLI F, 1978, CANCER TREAT REP, V62, P473
  • [9] Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer
    Choi, NC
    Herndon, JE
    Rosenman, J
    Carey, RW
    Chung, CT
    Bernard, S
    Leone, L
    Seagren, S
    Green, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) : 3528 - 3536
  • [10] CHU E, 2001, CANC PRINCIPLES PRAC, V1, P289